Diana Sarfati
Diana Sarfati
Verified email at
Cited by
Cited by
The new measuring multimorbidity index predicted mortality better than Charlson and Elixhauser indices among the general population
J Stanley, D Sarfati
Journal of clinical epidemiology 92, 99-110, 2017
The impact of comorbidity on cancer and its treatment
D Sarfati, B Koczwara, C Jackson
CA: a cancer journal for clinicians 66 (4), 337-350, 2016
Global cancer incidence in older adults, 2012 and 2035: a population‐based study
S Pilleron, D Sarfati, M Janssen‐Heijnen, J Vignat, J Ferlay, F Bray, ...
International journal of cancer 144 (1), 49-58, 2019
Measuring cancer survival in populations: relative survival vs cancer-specific survival
D Sarfati, T Blakely, N Pearce
International journal of epidemiology 39 (2), 598-610, 2010
Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050
S Pilleron, E Soto‐Perez‐de‐Celis, J Vignat, J Ferlay, I Soerjomataram, ...
International journal of cancer 148 (3), 601-608, 2021
SF-36 health survey reliability, validity and norms for New Zealand
KM Scott, MI Tobias, D Sarfati, SJ Haslett
Australian and New Zealand journal of public health 23 (4), 401-406, 1999
Survival disparities in Indigenous and non-Indigenous New Zealanders with colon cancer: the role of patient comorbidity, treatment and health service factors
S Hill, D Sarfati, T Blakely, B Robson, G Purdie, J Chen, E Dennett, ...
Journal of Epidemiology & Community Health 64 (2), 117-123, 2010
Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers
H Fowler, A Belot, L Ellis, C Maringe, MA Luque-Fernandez, EN Njagi, ...
BMC cancer 20, 1-15, 2020
Review of methods used to measure comorbidity in cancer populations: no gold standard exists
D Sarfati
Journal of clinical epidemiology 65 (9), 924-933, 2012
The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study
D Sarfati, S Hill, T Blakely, B Robson, G Purdie, E Dennett, D Cormack, ...
BMC cancer 9, 1-10, 2009
Risk factors for cryptorchidism
JK Gurney, KA McGlynn, J Stanley, T Merriman, V Signal, C Shaw, ...
Nature Reviews Urology 14 (9), 534-548, 2017
Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis
J Gurney, C Shaw, J Stanley, V Signal, D Sarfati
BMC cancer 15, 1-10, 2015
International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries
JK Gurney, AA Florio, A Znaor, J Ferlay, M Laversanne, D Sarfati, F Bray, ...
European urology 76 (5), 615-623, 2019
The impact of patient comorbidity on cancer stage at diagnosis
J Gurney, D Sarfati, J Stanley
British journal of cancer 113 (9), 1375-1380, 2015
A challenge to the cross-cultural validity of the SF-36 health survey: Factor structure in Māori, Pacific and New Zealand European ethnic groups
KM Scott, D Sarfati, MI Tobias, SJ Haslett
Social Science & Medicine 51 (11), 1655-1664, 2000
Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review
J Stairmand, L Signal, D Sarfati, C Jackson, L Batten, M Holdaway, ...
Annals of Oncology 26 (7), 1325-1332, 2015
Risk of lower limb amputation in a national prevalent cohort of patients with diabetes
JK Gurney, J Stanley, S York, D Rosenbaum, D Sarfati
Diabetologia 61, 626-635, 2018
Does the frame affect the picture? A study into how attitudes to screening for cancer are affected by the way benefits are expressed
D Sarfati, P Howden-Chapman, A Woodward, C Salmond
Journal of Medical Screening 5 (3), 137-140, 1998
Indigenous inequalities in cancer: what role for health care?
S Hill, D Sarfati, B Robson, T Blakely
ANZ journal of surgery 83 (1-2), 36-41, 2013
Changing global policy to deliver safe, equitable, and affordable care for women’s cancers
O Ginsburg, R Badwe, P Boyle, G Derricks, A Dare, T Evans, A Eniu, ...
The Lancet 389 (10071), 871-880, 2017
The system can't perform the operation now. Try again later.
Articles 1–20